114 related articles for article (PubMed ID: 28350209)
41. Toll-like receptor 9 trafficking and signaling for type I interferons requires PIKfyve activity.
Hayashi K; Sasai M; Iwasaki A
Int Immunol; 2015 Sep; 27(9):435-45. PubMed ID: 25925170
[TBL] [Abstract][Full Text] [Related]
42. Vacuolin-1 potently and reversibly inhibits autophagosome-lysosome fusion by activating RAB5A.
Lu Y; Dong S; Hao B; Li C; Zhu K; Guo W; Wang Q; Cheung KH; Wong CW; Wu WT; Markus H; Yue J
Autophagy; 2014; 10(11):1895-905. PubMed ID: 25483964
[TBL] [Abstract][Full Text] [Related]
43. CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma.
Dakappagari N; Ho SN; Gascoyne RD; Ranuio J; Weng AP; Tangri S
Cytometry B Clin Cytom; 2012 Mar; 82(2):112-9. PubMed ID: 22076940
[TBL] [Abstract][Full Text] [Related]
44. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
[TBL] [Abstract][Full Text] [Related]
45. Low grade malignant non-Hodgkin's lymphomas and peripheral pleomorphic T-cell lymphomas in childhood--a BFM study group report.
Bucsky P; Feller AC; Reiter A; Beck J; Bertram U; Eschenbach C; Gerein V; Lakomek M; Stollmann B; Tausch W
Klin Padiatr; 1990; 202(4):258-61. PubMed ID: 2203939
[TBL] [Abstract][Full Text] [Related]
46. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
Wanner K; Hipp S; Oelsner M; Ringshausen I; Bogner C; Peschel C; Decker T
Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
[TBL] [Abstract][Full Text] [Related]
47. Class III PI 3-kinase is the main source of PtdIns3P substrate and membrane recruitment signal for PIKfyve constitutive function in podocyte endomembrane homeostasis.
Ikonomov OC; Sbrissa D; Venkatareddy M; Tisdale E; Garg P; Shisheva A
Biochim Biophys Acta; 2015 May; 1853(5):1240-50. PubMed ID: 25619930
[TBL] [Abstract][Full Text] [Related]
48. Bruton's tyrosine kinase inhibitors: lessons learned from bench-to-bedside (first) studies.
Ysebaert L; Michallet AS
Curr Opin Oncol; 2014 Sep; 26(5):463-8. PubMed ID: 25033375
[TBL] [Abstract][Full Text] [Related]
49. PIKfyve controls dendritic cell function and tumor immunity.
Choi JE; Qiao Y; Kryczek I; Yu J; Gurkan J; Bao Y; Gondal M; Tien JC; Maj T; Yazdani S; Parolia A; Xia H; Zhou J; Wei S; Grove S; Vatan L; Lin H; Li G; Zheng Y; Zhang Y; Cao X; Su F; Wang R; He T; Cieslik M; Green MD; Zou W; Chinnaiyan AM
bioRxiv; 2024 Mar; ():. PubMed ID: 38464258
[TBL] [Abstract][Full Text] [Related]
50. Requirement for PIKfyve enzymatic activity in acute and long-term insulin cellular effects.
Ikonomov OC; Sbrissa D; Mlak K; Shisheva A
Endocrinology; 2002 Dec; 143(12):4742-54. PubMed ID: 12446602
[TBL] [Abstract][Full Text] [Related]
51. Salmonella vacuole maturation: PIKfyve leads the way.
Gutierrez MG
EMBO J; 2010 Apr; 29(8):1316-7. PubMed ID: 20407474
[No Abstract] [Full Text] [Related]
52. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
53. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.
Conlan MG; Bast M; Armitage JO; Weisenburger DD
J Clin Oncol; 1990 Jul; 8(7):1163-72. PubMed ID: 1694234
[TBL] [Abstract][Full Text] [Related]
54. Repetitive stimulation of autophagy-lysosome machinery by intermittent fasting preconditions the myocardium to ischemia-reperfusion injury.
Godar RJ; Ma X; Liu H; Murphy JT; Weinheimer CJ; Kovacs A; Crosby SD; Saftig P; Diwan A
Autophagy; 2015; 11(9):1537-60. PubMed ID: 26103523
[TBL] [Abstract][Full Text] [Related]
55. LY294002-mediated inhibition of phosphatidylinositol 3-kinase activity triggers growth inhibition and apoptosis in CD40-triggered Ramos-Burkitt lymphoma B cells.
Curnock AP; Knox KA
Cell Immunol; 1998 Aug; 187(2):77-87. PubMed ID: 9732695
[TBL] [Abstract][Full Text] [Related]
56. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
Kreuz S; Holmes KB; Tooze RM; Lefevre PF
Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
[TBL] [Abstract][Full Text] [Related]
57. PIKfyve, MTMR3 and their product PtdIns5P regulate cancer cell migration and invasion through activation of Rac1.
Oppelt A; Haugsten EM; Zech T; Danielsen HE; Sveen A; Lobert VH; Skotheim RI; Wesche J
Biochem J; 2014 Aug; 461(3):383-90. PubMed ID: 24840251
[TBL] [Abstract][Full Text] [Related]
58. Chloroquine overcomes resistance of lung carcinoma cells to the dual PI3K/mTOR inhibitor PI103 by lysosome-mediated apoptosis.
Enzenmüller S; Gonzalez P; Debatin KM; Fulda S
Anticancer Drugs; 2013 Jan; 24(1):14-9. PubMed ID: 23111416
[TBL] [Abstract][Full Text] [Related]
59. Curcumin enhances the response of non-Hodgkin's lymphoma cells to ionizing radiation through further induction of cell cycle arrest at the G2/M phase and inhibition of mTOR phosphorylation.
Qiao Q; Jiang Y; Li G
Oncol Rep; 2013 Jan; 29(1):380-6. PubMed ID: 23117293
[TBL] [Abstract][Full Text] [Related]
60. Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation.
Chapuy B; Schuelper N; Panse M; Dohm A; Hand E; Schroers R; Truemper L; Wulf GG
Br J Haematol; 2011 Feb; 152(4):401-12. PubMed ID: 21689083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
